Evidence map›Paper›PMID 27056899›Full record

Trial reportOncotarget2016

A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial.

Melanie Spears, Nicola Lyttle, Alister D'Costa, Bingshu E Chen, Cindy Q Yao, Paul C Boutros, Margot Burnell, Mark N Levine, Patti O'Brien, Lois Shepherd and 1 more

Open access · diamondAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Melanie SpearsTransformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada.
Nicola LyttleTransformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada.
Alister D'CostaTransformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada.
Bingshu E ChenNCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada.
Cindy Q YaoTransformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada.
Paul C BoutrosInformatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada.
Margot BurnellSaint John Regional Hospital, Saint John, MB, Canada.
Mark N LevineOntario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada.
Patti O'BrienNCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada.
Lois ShepherdNCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada.
John M S BartlettTransformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada.
Ontario Institute for Cancer Research · CAQueen's University · CAUniversity of Toronto · CAOntario Clinical Oncology Group · CASaint John Regional Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent evidence demonstrated CIN4 as a predictive marker of anthracycline benefit in early breast cancer. An analysis of the NCIC CTG MA.21 clinical trial was performed to test the role of existing CIN gene expression signatures as prognostic and predictive markers in the context of taxane based chemotherapy.RNA was extracted from patients in cyclophosphamide, epirubicin and flurouracil (CEF) and epirubicin, cyclophosphamide and paclitaxel (EC/T) arms of the NCIC CTG MA.21 trial and analysed using NanoString technology.After multivariate analysis both high CIN25 and CIN70 score was significantly associated with an increased in RFS (HR 1.76, 95%CI 1.07-2.86, p=0.0018 and HR 1.59, 95%CI 1.12-2.25, p=0.0096 respectively). Patients whose tumours had low CIN4 gene expression scores were associated with an increase in RFS (HR: 0.64, 95% CI 0.39-1.03, p=0.06) when treated with EC/T compared to patients treated with CEF.In conclusion we have demonstrated CIN25 and CIN70 as prognostic markers in breast cancer and that CIN4 is a potential predictive maker of benefit from taxane treatment.

Indexed as

Chromosomal InstabilityAdultAgedAnthracyclinesAntibiotics, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalEpirubicinFemaleFluorouracilGene Expression ProfilingAnthracyclinesAntibiotics, AntineoplasticAntineoplastic AgentsBiomarkers, TumorCyclophosphamideEpirubicinFluorouracilPaclitaxelTaxoidsanthracyclinebreast cancerchromosome instabilitypredictive biomarkertaxane

Identifiers

PMID27056899
PMCPMC5226493
OpenAlexW2313415525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.